Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Roy S Herbst, Jean-Charles Soria, +19 authors, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger, Holbrook E K Kohrt, Leora Horn, Donald P Lawrence, Sandra Rost, Maya Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S Hegde, Ira Mellman, Daniel S Chen, F Stephen Hodi. less Nature, 2014 Nov 28; 515(7528). PMID: 25428504 Free PMC article. Highly Cited.
|
CTLA-4 is a second receptor for the B cell activation antigen B7. P S Linsley, W Brady, +3 authors, M Urnes, L S Grosmaire, N K Damle, J A Ledbetter. less J Exp Med, 1991 Sep 01; 174(3). PMID: 1714933 Free PMC article. Highly Cited.
|
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. H Nishimura, T Okazaki, +8 authors, Y Tanaka, K Nakatani, M Hara, A Matsumori, S Sasayama, A Mizoguchi, H Hiai, N Minato, T Honjo. less Science, 2001 Feb 24; 291(5502). PMID: 11209085 Highly Cited.
|
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Chih-Hao Chang, Jing Qiu, +11 authors, David O'Sullivan, Michael D Buck, Takuro Noguchi, Jonathan D Curtis, Qiongyu Chen, Mariel Gindin, Matthew M Gubin, Gerritje J W van der Windt, Elena Tonc, Robert D Schreiber, Edward J Pearce, Erika L Pearce. less Cell, 2015 Sep 01; 162(6). PMID: 26321679 Free PMC article. Highly Cited.
|
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Scott J Antonia, Augusto Villegas, +28 authors, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit, Byoung C Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E Gray, Luis Paz-Ares, Javier de Castro Carpeño, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A Dennis, Mustafa Özgüroğlu, PACIFIC Investigators. less N Engl J Med, 2017 Sep 09; 377(20). PMID: 28885881 Highly Cited.
|
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. Robert L Ferris, George Blumenschein, +20 authors, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara C Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J Geese, Justin Kopit, James W Shaw, Maura L Gillison. less N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718784 Free PMC article. Highly Cited.
|
Genetic basis for clinical response to CTLA-4 blockade in melanoma. Alexandra Snyder, Vladimir Makarov, +18 authors, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho, Travis J Hollmann, Cameron Bruggeman, Kasthuri Kannan, Yanyun Li, Ceyhan Elipenahli, Cailian Liu, Christopher T Harbison, Lisu Wang, Antoni Ribas, Jedd D Wolchok, Timothy A Chan. less N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260 Free PMC article. Highly Cited.
|
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Peter Schmid, Sylvia Adams, +16 authors, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright, Volkmar Henschel, Luciana Molinero, Stephen Y Chui, Roel Funke, Amreen Husain, Eric P Winer, Sherene Loi, Leisha A Emens, IMpassion130 Trial Investigators. less N Engl J Med, 2018 Oct 23; 379(22). PMID: 30345906 Highly Cited.
|
Immune-related cutaneous adverse events due to checkpoint inhibitors. Evelyn Wang, Lukas Kraehenbuehl, +3 authors, Kwami Ketosugbo, Jeffrey A Kern, Mario E Lacouture, Donald Y M Leung. less Ann Allergy Asthma Immunol, 2021 Feb 21; 126(6). PMID: 33609771 Free PMC article. Review.
|
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Jason Madore, Ricardo E Vilain, +9 authors, Alexander M Menzies, Hojabr Kakavand, James S Wilmott, Jessica Hyman, Jennifer H Yearley, Richard F Kefford, John F Thompson, Georgina V Long, Peter Hersey, Richard A Scolyer. less Pigment Cell Melanoma Res, 2014 Dec 06; 28(3). PMID: 25477049 Highly Cited.
|
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. P S Linsley, J L Greene, +3 authors, W Brady, J Bajorath, J A Ledbetter, R Peach. less Immunity, 1994 Dec 01; 1(9). PMID: 7534620 Highly Cited.
|
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho, Martin L Miller, Natasha Rekhtman, Andre L Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B Garon, Taha Merghoub, Jedd D Wolchok, Ton N Schumacher, Timothy A Chan. less Science, 2015 Mar 15; 348(6230). PMID: 25765070 Free PMC article. Highly Cited.
|
Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. E Chuang, K M Lee, +6 authors, M D Robbins, J M Duerr, M L Alegre, J E Hambor, M J Neveu, J A Bluestone, C B Thompson. less J Immunol, 1999 Feb 11; 162(3). PMID: 9973379
|
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. Patrick M Forde, Jamie E Chaft, Drew M Pardoll. N Engl J Med, 2018 Aug 30; 379(9). PMID: 30157404
|
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta M Retz, Petros Grivas, Richard W Joseph, Matthew D Galsky, Mark T Fleming, Daniel P Petrylak, Jose Luis Perez-Gracia, Howard A Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M Frampton, Na Cui, Sanjeev Mariathasan, Oyewale Abidoye, Gregg D Fine, Robert Dreicer. less Lancet, 2016 Mar 10; 387(10031). PMID: 26952546 Free PMC article. Highly Cited.
|
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Jian Wang, Taku Yoshida, +3 authors, Fumio Nakaki, Hiroshi Hiai, Taku Okazaki, Tasuku Honjo. less Proc Natl Acad Sci U S A, 2005 Aug 10; 102(33). PMID: 16087865 Free PMC article. Highly Cited.
|
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Roy S Herbst, Paul Baas, +16 authors, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon. less Lancet, 2015 Dec 30; 387(10027). PMID: 26712084 Highly Cited.
|
A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. Tie Zheng Hou, Omar S Qureshi, +4 authors, Chun Jing Wang, Jennifer Baker, Stephen P Young, Lucy S K Walker, David M Sansom. less J Immunol, 2015 Jan 30; 194(5). PMID: 25632005 Free PMC article.
|
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nikolaos Patsoukis, Kankana Bardhan, +9 authors, Pranam Chatterjee, Duygu Sari, Bianling Liu, Lauren N Bell, Edward D Karoly, Gordon J Freeman, Victoria Petkova, Pankaj Seth, Lequn Li, Vassiliki A Boussiotis. less Nat Commun, 2015 Mar 27; 6. PMID: 25809635 Free PMC article. Highly Cited.
|
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Anthony B El-Khoueiry, Bruno Sangro, +18 authors, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling, Tim Meyer, Yoon-Koo Kang, Winnie Yeo, Akhil Chopra, Jeffrey Anderson, Christine Dela Cruz, Lixin Lang, Jaclyn Neely, Hao Tang, Homa B Dastani, Ignacio Melero. less Lancet, 2017 Apr 25; 389(10088). PMID: 28434648 Free PMC article. Highly Cited.
|
PD-1 signaling in primary T cells. James L Riley. Immunol Rev, 2009 May 12; 229(1). PMID: 19426218 Free PMC article. Highly Cited. Review.
|
Improved survival with ipilimumab in patients with metastatic melanoma. F Stephen Hodi, Steven J O'Day, +26 authors, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akerley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, Christian H Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, Jedd D Wolchok, Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, Axel Hoos, Walter J Urba. less N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992 Free PMC article. Highly Cited.
|
PD-1 and its ligands in tolerance and immunity. Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375 Highly Cited. Review.
|
Molecular mechanisms of T cell co-stimulation and co-inhibition. Lieping Chen, Dallas B Flies. Nat Rev Immunol, 2013 Mar 09; 13(4). PMID: 23470321 Free PMC article. Highly Cited. Review.
|
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Jeffrey S Weber, Sandra P D'Angelo, +25 authors, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao, Gerald P Linette, Luc Thomas, Paul Lorigan, Kenneth F Grossmann, Jessica C Hassel, Michele Maio, Mario Sznol, Paolo A Ascierto, Peter Mohr, Bartosz Chmielowski, Alan Bryce, Inge M Svane, Jean-Jacques Grob, Angela M Krackhardt, Christine Horak, Alexandre Lambert, Arvin S Yang, James Larkin. less Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410 Highly Cited.
|
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Padmanee Sharma, Margitta Retz, +16 authors, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta Pal, Chikara Ohyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D Galsky. less Lancet Oncol, 2017 Jan 31; 18(3). PMID: 28131785 Highly Cited.
|
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Lidia Robert, Jennifer Tsoi, +11 authors, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Rong Huang, Alistair J Cochran, Begoña Comin-Anduix, Richard C Koya, Thomas G Graeber, Harlan Robins, Antoni Ribas. less Clin Cancer Res, 2014 Mar 04; 20(9). PMID: 24583799 Free PMC article. Highly Cited.
|
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Dirk Schadendorf, F Stephen Hodi, +7 authors, Caroline Robert, Jeffrey S Weber, Kim Margolin, Omid Hamid, Debra Patt, Tai-Tsang Chen, David M Berman, Jedd D Wolchok. less J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295 Free PMC article. Highly Cited.
|
CTLA-4 regulates induction of anergy in vivo. R J Greenwald, V A Boussiotis, +2 authors, R B Lorsbach, A K Abbas, A H Sharpe. less Immunity, 2001 Mar 10; 14(2). PMID: 11239447 Highly Cited.
|
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Brian T Fife, Jeffrey A Bluestone. Immunol Rev, 2008 Sep 02; 224. PMID: 18759926 Highly Cited. Review.
|
Acquired Resistance to Immune Checkpoint Inhibitors. Adam J Schoenfeld, Matthew D Hellmann. Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289269 Free PMC article. Review.
|
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Manish R Patel, John Ellerton, +15 authors, Jeffrey R Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D Britten, Luc Dirix, Keun-Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B Gelb, Junyuan Xiong, Galit Rosen, James L Gulley, Andrea B Apolo. less Lancet Oncol, 2017 Dec 09; 19(1). PMID: 29217288 Free PMC article. Highly Cited.
|
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Shogo Kumagai, Yosuke Togashi, +28 authors, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Kochin Vitaly, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui, Takuma Shibahara, Yasuho Yamashita, Takuma Irie, Ayaka Tsuge, Shota Fukuoka, Akihito Kawazoe, Hibiki Udagawa, Keisuke Kirita, Keiju Aokage, Genichiro Ishii, Takeshi Kuwata, Kenta Nakama, Masahito Kawazu, Toshihide Ueno, Naoya Yamazaki, Koichi Goto, Masahiro Tsuboi, Hiroyuki Mano, Toshihiko Doi, Kohei Shitara, Hiroyoshi Nishikawa. less Nat Immunol, 2020 Sep 02; 21(11). PMID: 32868929
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Suzanne L Topalian, F Stephen Hodi, +27 authors, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins, Philip D Leming, David R Spigel, Scott J Antonia, Leora Horn, Charles G Drake, Drew M Pardoll, Lieping Chen, William H Sharfman, Robert A Anders, Janis M Taube, Tracee L McMiller, Haiying Xu, Alan J Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D Kollia, Ashok Gupta, Jon M Wigginton, Mario Sznol. less N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127 Free PMC article. Highly Cited.
|
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Nikolaos Patsoukis, Julia Brown, +3 authors, Victoria Petkova, Fang Liu, Lequn Li, Vassiliki A Boussiotis. less Sci Signal, 2012 Jun 29; 5(230). PMID: 22740686 Free PMC article. Highly Cited.
|
Nivolumab in previously untreated melanoma without BRAF mutation. Caroline Robert, Georgina V Long, +25 authors, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Kerry J Savage, Micaela M Hernberg, Celeste Lebbé, Julie Charles, Catalin Mihalcioiu, Vanna Chiarion-Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, Lotta Lundgren-Eriksson, Christine Horak, Brian Sharkey, Ian M Waxman, Victoria Atkinson, Paolo A Ascierto. less N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552 Highly Cited.
|
CTLA-4 can function as a negative regulator of T cell activation. T L Walunas, D J Lenschow, +5 authors, C Y Bakker, P S Linsley, G J Freeman, J M Green, C B Thompson, J A Bluestone. less Immunity, 1994 Aug 01; 1(5). PMID: 7882171 Highly Cited.
|
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. Xiaozhou Fan, Sergio A Quezada, +2 authors, Manuel A Sepulveda, Padmanee Sharma, James P Allison. less J Exp Med, 2014 Apr 02; 211(4). PMID: 24687957 Free PMC article. Highly Cited.
|
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. J M Michot, C Bigenwald, +21 authors, S Champiat, M Collins, F Carbonnel, S Postel-Vinay, A Berdelou, A Varga, R Bahleda, A Hollebecque, C Massard, A Fuerea, V Ribrag, A Gazzah, J P Armand, N Amellal, E Angevin, N Noel, C Boutros, C Mateus, C Robert, J C Soria, A Marabelle, O Lambotte. less Eur J Cancer, 2016 Jan 15; 54. PMID: 26765102 Highly Cited. Review.
|
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. G J Freeman, A J Long, +16 authors, Y Iwai, K Bourque, T Chernova, H Nishimura, L J Fitz, N Malenkovich, T Okazaki, M C Byrne, H F Horton, L Fouser, L Carter, V Ling, M R Bowman, B M Carreno, M Collins, C R Wood, T Honjo. less J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443 Free PMC article. Highly Cited.
|
Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. P Dariavach, M G Mattéi, P Golstein, M P Lefranc. Eur J Immunol, 1988 Dec 01; 18(12). PMID: 3220103
|
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Jeffrey Weber, Mario Mandala, +32 authors, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Jean-Jacques Grob, Marcus O Butler, Mark R Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, Rene Gonzalez, Ragini R Kudchadkar, Michael Smylie, Nicolas Meyer, Laurent Mortier, Michael B Atkins, Georgina V Long, Shailender Bhatia, Celeste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A Ascierto, CheckMate 238 Collaborators. less N Engl J Med, 2017 Sep 12; 377(19). PMID: 28891423 Highly Cited.
|
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. F Stephen Hodi, Martin C Mihm, +14 authors, Robert J Soiffer, Frank G Haluska, Marcus Butler, Michael V Seiden, Thomas Davis, Rochele Henry-Spires, Suzanne MacRae, Ann Willman, Robert Padera, Michael T Jaklitsch, Sridhar Shankar, Teresa C Chen, Alan Korman, James P Allison, Glenn Dranoff. less Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289 Free PMC article. Highly Cited.
|
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. H Nishimura, M Nose, +2 authors, H Hiai, N Minato, T Honjo. less Immunity, 1999 Sep 15; 11(2). PMID: 10485649 Highly Cited.
|
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Edward Cha, Mark Klinger, +4 authors, Yafei Hou, Craig Cummings, Antoni Ribas, Malek Faham, Lawrence Fong. less Sci Transl Med, 2014 May 30; 6(238). PMID: 24871131 Free PMC article. Highly Cited.
|
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Martin Reck, Delvys Rodríguez-Abreu, +16 authors, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, KEYNOTE-024 Investigators. less N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847 Highly Cited.
|
Moving towards personalized treatments of immune-related adverse events. Khashayar Esfahani, Arielle Elkrief, +5 authors, Cassandra Calabrese, Réjean Lapointe, Marie Hudson, Bertrand Routy, Wilson H Miller, Leonard Calabrese. less Nat Rev Clin Oncol, 2020 Apr 05; 17(8). PMID: 32246128 Review.
|
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Howard L Kaufman, Jeffery Russell, +15 authors, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D'Angelo, Kent C Shih, Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem. less Lancet Oncol, 2016 Sep 07; 17(10). PMID: 27592805 Free PMC article. Highly Cited.
|
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. P Waterhouse, J M Penninger, +6 authors, E Timms, A Wakeham, A Shahinian, K P Lee, C B Thompson, H Griesser, T W Mak. less Science, 1995 Nov 10; 270(5238). PMID: 7481803 Highly Cited.
|
The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. E Chuang, T S Fisher, +7 authors, R W Morgan, M D Robbins, J M Duerr, M G Vander Heiden, J P Gardner, J E Hambor, M J Neveu, C B Thompson. less Immunity, 2000 Oct 06; 13(3). PMID: 11021529
|
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Paul C Tumeh, Christina L Harview, +23 authors, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio J Gutierrez, Tristan R Grogan, Christine Mateus, Gorana Tomasic, John A Glaspy, Ryan O Emerson, Harlan Robins, Robert H Pierce, David A Elashoff, Caroline Robert, Antoni Ribas. less Nature, 2014 Nov 28; 515(7528). PMID: 25428505 Free PMC article. Highly Cited.
|
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704 Highly Cited. Review.
|
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Achim Rittmeyer, Fabrice Barlesi, +23 authors, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols, Diego L Cortinovis, Joseph Leach, Jonathan Polikoff, Carlos Barrios, Fairooz Kabbinavar, Osvaldo Arén Frontera, Filippo De Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S Chen, Alan Sandler, David R Gandara, OAK Study Group. less Lancet, 2016 Dec 17; 389(10066). PMID: 27979383 Free PMC article. Highly Cited.
|
CTLA-4 control over Foxp3+ regulatory T cell function. Kajsa Wing, Yasushi Onishi, +5 authors, Paz Prieto-Martin, Tomoyuki Yamaguchi, Makoto Miyara, Zoltan Fehervari, Takashi Nomura, Shimon Sakaguchi. less Science, 2008 Oct 11; 322(5899). PMID: 18845758 Highly Cited.
|
Immune checkpoint inhibitor-related dermatologic adverse events. Amaris N Geisler, Gregory S Phillips, +5 authors, Dulce M Barrios, Jennifer Wu, Donald Y M Leung, Andrea P Moy, Jeffrey A Kern, Mario E Lacouture. less J Am Acad Dermatol, 2020 May 27; 83(5). PMID: 32454097 Free PMC article. Review.
|
The B7 family revisited. Rebecca J Greenwald, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol, 2005 Mar 18; 23. PMID: 15771580 Highly Cited. Review.
|
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Manish J Butte, Mary E Keir, +2 authors, Theresa B Phamduy, Arlene H Sharpe, Gordon J Freeman. less Immunity, 2007 Jul 17; 27(1). PMID: 17629517 Free PMC article. Highly Cited.
|
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Andrew M Intlekofer, Craig B Thompson. J Leukoc Biol, 2013 Apr 30; 94(1). PMID: 23625198 Free PMC article. Highly Cited. Review.
|
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Filipe Martins, Latifyan Sofiya, +14 authors, Gerasimos P Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier, Thierry Kuntzer, Olivier Michielin, Solange Peters, Georges Coukos, Francois Spertini, John A Thompson, Michel Obeid. less Nat Rev Clin Oncol, 2019 May 17; 16(9). PMID: 31092901 Highly Cited. Review.
|
Why are immune adverse events so common with checkpoint inhibitor therapy? Taras Lyubchenko, Donald Y M Leung, Elena Goleva. Ann Allergy Asthma Immunol, 2021 Mar 29; 126(6). PMID: 33774187 Free PMC article.
|
Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. Mohamed A ElTanbouly, Randolph J Noelle. Nat Rev Immunol, 2020 Oct 21; 21(4). PMID: 33077935 Review.
|
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Vivek Kumar, Neha Chaudhary, +3 authors, Mohit Garg, Charalampos S Floudas, Parita Soni, Abhinav B Chandra. less Front Pharmacol, 2017 Feb 24; 8. PMID: 28228726 Free PMC article. Highly Cited. Review.
|
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. M F Krummel, J P Allison. J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139 Free PMC article. Highly Cited.
|
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Robert Chen, Pier Luigi Zinzani, +15 authors, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A Shipp, Yinghua Zhang, Alejandro D Ricart, Arun Balakumaran, Craig H Moskowitz, KEYNOTE-087. less J Clin Oncol, 2017 Apr 26; 35(19). PMID: 28441111 Free PMC article. Highly Cited.
|
Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. Fiamma Berner, David Bomze, Lukas Flatz. JAMA Oncol, 2019 Oct 04;. PMID: 31580393
|
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. M Fehlings, Y Simoni, +7 authors, H L Penny, E Becht, C Y Loh, M M Gubin, J P Ward, S C Wong, R D Schreiber, E W Newell. less Nat Commun, 2017 Sep 17; 8(1). PMID: 28916749 Free PMC article.
|
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Tihui Fu, Qiuming He, Padmanee Sharma. Cancer Res, 2011 Jun 29; 71(16). PMID: 21708958
|
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Lukas F Mager, Regula Burkhard, +10 authors, Nicola Pett, Noah C A Cooke, Kirsty Brown, Hena Ramay, Seungil Paik, John Stagg, Ryan A Groves, Marco Gallo, Ian A Lewis, Markus B Geuking, Kathy D McCoy. less Science, 2020 Aug 15; 369(6510). PMID: 32792462
|
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Richard V Parry, Jens M Chemnitz, +6 authors, Kenneth A Frauwirth, Anthony R Lanfranco, Inbal Braunstein, Sumire V Kobayashi, Peter S Linsley, Craig B Thompson, James L Riley. less Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604 Free PMC article. Highly Cited.
|
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Udupi A Ramagopal, Weifeng Liu, +10 authors, Sarah C Garrett-Thomson, Jeffrey B Bonanno, Qingrong Yan, Mohan Srinivasan, Susan C Wong, Alasdair Bell, Shilpa Mankikar, Vangipuram S Rangan, Shrikant Deshpande, Alan J Korman, Steven C Almo. less Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017 Free PMC article.
|
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. Nienke van Rooij, Marit M van Buuren, +14 authors, Daisy Philips, Arno Velds, Mireille Toebes, Bianca Heemskerk, Laura J A van Dijk, Sam Behjati, Henk Hilkmann, Dris El Atmioui, Marja Nieuwland, Michael R Stratton, Ron M Kerkhoven, Can Kesmir, John B Haanen, Pia Kvistborg, Ton N Schumacher. less J Clin Oncol, 2013 Sep 18; 31(32). PMID: 24043743 Free PMC article. Highly Cited.
|
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med, 2018 Jan 11; 378(2). PMID: 29320654 Highly Cited. Review.
|
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. M F Krummel, J P Allison. J Exp Med, 1996 Jun 01; 183(6). PMID: 8676074 Free PMC article. Highly Cited.
|
A guide to cancer immunotherapy: from T cell basic science to clinical practice. Alex D Waldman, Jill M Fritz, Michael J Lenardo. Nat Rev Immunol, 2020 May 21; 20(11). PMID: 32433532 Free PMC article. Review.
|
Nivolumab plus ipilimumab in advanced melanoma. Jedd D Wolchok, Harriet Kluger, +21 authors, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M Burke, Anne Caldwell, Stephanie A Kronenberg, Blessing U Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E Horak, Quan Hong, Alan J Korman, Jon M Wigginton, Ashok Gupta, Mario Sznol. less N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867 Free PMC article. Highly Cited.
|
Neoantigens in cancer immunotherapy. Ton N Schumacher, Robert D Schreiber. Science, 2015 Apr 04; 348(6230). PMID: 25838375 Highly Cited. Review.
|
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Seng-Ryong Woo, Meghan E Turnis, +18 authors, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F Grosso, George Netto, Matthew P Smeltzer, Alcides Chaux, Paul J Utz, Creg J Workman, Drew M Pardoll, Alan J Korman, Charles G Drake, Dario A A Vignali. less Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141 Free PMC article. Highly Cited.
|
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Rony Dahan, Emanuela Sega, +3 authors, John Engelhardt, Mark Selby, Alan J Korman, Jeffrey V Ravetch. less Cancer Cell, 2015 Sep 17; 28(3). PMID: 26373277 Highly Cited.
|
A new member of the immunoglobulin superfamily--CTLA-4. J F Brunet, F Denizot, +4 authors, M F Luciani, M Roux-Dosseto, M Suzan, M G Mattei, P Golstein. less Nature, 1987 Jul 16; 328(6127). PMID: 3496540 Highly Cited.
|
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. Thomas Powles, Peter H O'Donnell, +16 authors, Christophe Massard, Hendrik-Tobias Arkenau, Terence W Friedlander, Christopher J Hoimes, Jae Lyun Lee, Michael Ong, Srikala S Sridhar, Nicholas J Vogelzang, Mayer N Fishman, Jingsong Zhang, Sandy Srinivas, Jigar Parikh, Joyce Antal, Xiaoping Jin, Ashok K Gupta, Yong Ben, Noah M Hahn. less JAMA Oncol, 2017 Aug 18; 3(9). PMID: 28817753 Free PMC article. Highly Cited.
|
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Tadashi Yokosuka, Masako Takamatsu, +3 authors, Wakana Kobayashi-Imanishi, Akiko Hashimoto-Tane, Miyuki Azuma, Takashi Saito. less J Exp Med, 2012 May 30; 209(6). PMID: 22641383 Free PMC article. Highly Cited.
|
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. Joaquim Bellmunt, Ronald de Wit, +18 authors, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I Quinn, Stéphane Culine, Cora N Sternberg, Yabing Mai, Christian H Poehlein, Rodolfo F Perini, Dean F Bajorin, KEYNOTE-045 Investigators. less N Engl J Med, 2017 Feb 18; 376(11). PMID: 28212060 Free PMC article. Highly Cited.
|
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Kristian M Hargadon, Coleman E Johnson, Corey J Williams. Int Immunopharmacol, 2018 Jul 11; 62. PMID: 29990692 Highly Cited. Review.
|
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. Tyler R Simpson, Fubin Li, +11 authors, Welby Montalvo-Ortiz, Manuel A Sepulveda, Katharina Bergerhoff, Frederick Arce, Claire Roddie, Jake Y Henry, Hideo Yagita, Jedd D Wolchok, Karl S Peggs, Jeffrey V Ravetch, James P Allison, Sergio A Quezada. less J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981 Free PMC article. Highly Cited.
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Ezra E W Cohen, Denis Soulières, +13 authors, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan Cheng, Ramona F Swaby, Kevin J Harrington, KEYNOTE-040 investigators. less Lancet, 2018 Dec 05; 393(10167). PMID: 30509740 Highly Cited.
|
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Derek Ng Tang, Yu Shen, +5 authors, Jingjing Sun, Sijin Wen, Jedd D Wolchok, Jianda Yuan, James P Allison, Padmanee Sharma. less Cancer Immunol Res, 2014 Apr 30; 1(4). PMID: 24777852 Free PMC article. Highly Cited.
|
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. P'ng Loke, James P Allison. Proc Natl Acad Sci U S A, 2003 Apr 17; 100(9). PMID: 12697896 Free PMC article. Highly Cited.
|
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Leora Horn, Aaron S Mansfield, +19 authors, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S Shames, Juan Liu, Beiying Ding, Ariel Lopez-Chavez, Fairooz Kabbinavar, Wei Lin, Alan Sandler, Stephen V Liu, IMpower133 Study Group. less N Engl J Med, 2018 Oct 04; 379(23). PMID: 30280641 Highly Cited.
|
Pembrolizumab versus Ipilimumab in Advanced Melanoma. Caroline Robert, Jacob Schachter, +20 authors, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U Blank, Omid Hamid, Christine Mateus, Ronnie Shapira-Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas, KEYNOTE-006 investigators. less N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173 Highly Cited.
|
Tolerance in the Age of Immunotherapy. Jeffrey A Bluestone, Mark Anderson. N Engl J Med, 2020 Sep 17; 383(12). PMID: 32937048 Free PMC article. Review.
|
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Thomas Powles, Joseph Paul Eder, +12 authors, Gregg D Fine, Fadi S Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A Burris, Daniel P Petrylak, Siew-leng Teng, Xiaodong Shen, Zachary Boyd, Priti S Hegde, Daniel S Chen, Nicholas J Vogelzang. less Nature, 2014 Nov 28; 515(7528). PMID: 25428503 Highly Cited.
|
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. Karl S Peggs, Sergio A Quezada, +2 authors, Cynthia A Chambers, Alan J Korman, James P Allison. less J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407 Free PMC article. Highly Cited.
|
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Kaori Sakuishi, Lionel Apetoh, +3 authors, Jenna M Sullivan, Bruce R Blazar, Vijay K Kuchroo, Ana C Anderson. less J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927 Free PMC article. Highly Cited.
|
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Chrysoula I Liakou, Ashish Kamat, +5 authors, Derek Ng Tang, Hong Chen, Jingjing Sun, Patricia Troncoso, Christopher Logothetis, Padmanee Sharma. less Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309 Free PMC article. Highly Cited.
|
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. Charles S Fuchs, Toshihiko Doi, +26 authors, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A Wainberg, Daniel V Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H Ko, Geoffrey Ku, Philip Philip, Peter C Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Rosales, Rita P Dalal, Harry H Yoon. less JAMA Oncol, 2018 Mar 16; 4(5). PMID: 29543932 Free PMC article. Highly Cited.
|
Systemic Immunity Is Required for Effective Cancer Immunotherapy. Matthew H Spitzer, Yaron Carmi, +10 authors, Nathan E Reticker-Flynn, Serena S Kwek, Deepthi Madhireddy, Maria M Martins, Pier Federico Gherardini, Tyler R Prestwood, Jonathan Chabon, Sean C Bendall, Lawrence Fong, Garry P Nolan, Edgar G Engleman. less Cell, 2017 Jan 24; 168(3). PMID: 28111070 Free PMC article. Highly Cited.
|
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. Michael R Migden, Danny Rischin, +34 authors, Chrysalyne D Schmults, Alexander Guminski, Axel Hauschild, Karl D Lewis, Christine H Chung, Leonel Hernandez-Aya, Annette M Lim, Anne Lynn S Chang, Guilherme Rabinowits, Alesha A Thai, Lara A Dunn, Brett G M Hughes, Nikhil I Khushalani, Badri Modi, Dirk Schadendorf, Bo Gao, Frank Seebach, Siyu Li, Jingjin Li, Melissa Mathias, Jocelyn Booth, Kosalai Mohan, Elizabeth Stankevich, Hani M Babiker, Irene Brana, Marta Gil-Martin, Jade Homsi, Melissa L Johnson, Victor Moreno, Jiaxin Niu, Taofeek K Owonikoko, Kyriakos P Papadopoulos, George D Yancopoulos, Israel Lowy, Matthew G Fury. less N Engl J Med, 2018 Jun 05; 379(4). PMID: 29863979 Highly Cited.
|
The diverse functions of the PD1 inhibitory pathway. Arlene H Sharpe, Kristen E Pauken. Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585 Highly Cited. Review.
|
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Naiyer A Rizvi, Julien Mazières, +27 authors, David Planchard, Thomas E Stinchcombe, Grace K Dy, Scott J Antonia, Leora Horn, Hervé Lena, Elisa Minenza, Bertrand Mennecier, Gregory A Otterson, Luis T Campos, David R Gandara, Benjamin P Levy, Suresh G Nair, Gérard Zalcman, Jürgen Wolf, Pierre-Jean Souquet, Editta Baldini, Federico Cappuzzo, Christos Chouaid, Afshin Dowlati, Rachel Sanborn, Ariel Lopez-Chavez, Christian Grohe, Rudolf M Huber, Christopher T Harbison, Christine Baudelet, Brian J Lestini, Suresh S Ramalingam. less Lancet Oncol, 2015 Feb 24; 16(3). PMID: 25704439 Free PMC article. Highly Cited.
|
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Joseph F Grosso, Maria N Jure-Kunkel. Cancer Immun, 2013 Feb 08; 13. PMID: 23390376 Free PMC article. Highly Cited. Review.
|
Immune-related adverse events of checkpoint inhibitors. Manuel Ramos-Casals, Julie R Brahmer, +7 authors, Margaret K Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, Maria E Suárez-Almazor. less Nat Rev Dis Primers, 2020 May 10; 6(1). PMID: 32382051 Review.
|
Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. L E Marengère, P Waterhouse, +3 authors, G S Duncan, H W Mittrücker, G S Feng, T W Mak. less Science, 1996 May 24; 272(5265). PMID: 8638161 Highly Cited.
|
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. Stephen M Ansell, Alexander M Lesokhin, +16 authors, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman, Scott J Rodig, Bjoern Chapuy, Azra H Ligon, Lili Zhu, Joseph F Grosso, Su Young Kim, John M Timmerman, Margaret A Shipp, Philippe Armand. less N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239 Free PMC article. Highly Cited.
|
The future of immune checkpoint therapy. Padmanee Sharma, James P Allison. Science, 2015 Apr 04; 348(6230). PMID: 25838373 Highly Cited. Review.
|
CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. J H Fraser, M Rincón, K D McCoy, G Le Gros. Eur J Immunol, 1999 Mar 26; 29(3). PMID: 10092086
|
Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Xuguang Tai, François Van Laethem, +9 authors, Leonid Pobezinsky, Terry Guinter, Susan O Sharrow, Anthony Adams, Larry Granger, Michael Kruhlak, Tullia Lindsten, Craig B Thompson, Lionel Feigenbaum, Alfred Singer. less Blood, 2012 Mar 10; 119(22). PMID: 22403258 Free PMC article. Highly Cited.
|
Enhancement of antitumor immunity by CTLA-4 blockade. D R Leach, M F Krummel, J P Allison. Science, 1996 Mar 22; 271(5256). PMID: 8596936 Highly Cited.
|
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Tsvetelina Pentcheva-Hoang, Jackson G Egen, Kathleen Wojnoonski, James P Allison. Immunity, 2004 Sep 11; 21(3). PMID: 15357951 Highly Cited.
|